Profile data is unavailable for this security.
About the company
Avadel Pharmaceuticals, PLC is a specialty pharmaceutical company. The Company offers various drug delivery platforms, including Micropump, LiquiTime, Trigger Lock and Medusa. The Company offers its products in various categories, including hospital, including Bloxiverz, Vazculep and Akovaz, and pediatrics, including Karbinal ER, Cefaclor for Oral Suspension, AcipHex Sprinkle and Flexichamber. Bloxiverz is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Vazculep is used to treat clinically hypotension resulting primarily from vasodilation in the setting of anesthesia. Akovaz is indicated to treat clinically hypotension in the setting of anesthesia. Cefaclor is indicated for the treatment of otitis media, lower respiratory infections, pharyngitis and tonsillitis, urinary tract infections, and skin and skin structure infections, caused by susceptible organisms.
- Revenue in USD (TTM)86.41m
- Net income in USD-96.36m
- Incorporated2017
- Employees144.00
- LocationAvadel Pharmaceuticals PLCBlock 10-1 Blanchardstown Corporate ParkBallycoolinDUBLIN 15IrelandIRL
- Phone+353 14851200
- Fax+353 15261077
- Websitehttps://www.avadel.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fennec Pharmaceuticals Inc | 0.00 | -10.95m | 80.38m | 1.00 | -- | 4.19 | -- | -- | -0.5666 | -0.5666 | 0.00 | 0.9653 | 0.00 | -- | -- | -- | -46.10 | -46.88 | -48.79 | -54.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.33 | -- | -- | -- |
| Aclaris Therapeutics Inc | 14.01m | -140.07m | 81.72m | 169.00 | -- | 0.4484 | -- | 5.83 | -3.97 | -3.97 | 0.3948 | 4.42 | 0.0592 | -- | 1.71 | 82,923.08 | -59.13 | -41.46 | -66.11 | -43.78 | 38.20 | -- | -999.53 | -2,380.30 | 4.30 | -- | 0.1445 | -- | 499.58 | -- | -88.66 | -- | -- | -- |
| Catabasis Pharmaceuticals Inc | 0.00 | -24.26m | 82.10m | 24.00 | -- | 1.65 | -- | -- | -4.25 | -4.25 | 0.00 | 4.34 | 0.00 | -- | -- | 0.00 | -66.65 | -82.97 | -76.74 | -100.27 | -- | -- | -- | -28,761.60 | -- | -- | 0.00 | -- | -100.00 | -- | 5.46 | -- | -- | -- |
| Curis, Inc. | 9.73m | -31.71m | 82.88m | -- | -- | -- | -- | 8.52 | -0.9568 | -0.9568 | 0.2935 | -0.4141 | 0.1665 | -- | 4.55 | 313,774.20 | -54.29 | -64.35 | -64.85 | -77.32 | 94.43 | 2.27 | -326.02 | -491.53 | -- | -8.05 | -- | -- | 5.35 | -7.02 | 38.90 | -- | -11.09 | -- |
| Soleno Therapeutics Inc | 0.00 | -15.58m | 83.57m | 12.00 | -- | 3.54 | -- | -- | -0.6173 | -0.6614 | 0.00 | 0.7437 | 0.00 | -- | -- | -- | -41.44 | -59.29 | -43.89 | -73.28 | -- | -- | -- | -8,155.25 | -- | -81.36 | 0.00 | -- | -- | -- | -904.33 | -- | 44.50 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 86.41m | -96.36m | 83.68m | 144.00 | -- | -- | -- | 0.9683 | -2.60 | -2.59 | 2.33 | -0.2565 | 0.3289 | 2.78 | 6.07 | 600,090.30 | -36.67 | -11.50 | -47.36 | -16.26 | 83.58 | 89.94 | -111.51 | -19.49 | 3.13 | -6.29 | 1.08 | -- | -40.39 | 89.92 | -247.59 | -- | 81.34 | -- |
| Entasis Therapeutics Holdings Inc | 5.00m | -35.23m | 83.78m | 33.00 | -- | 1.19 | -- | 16.76 | -2.69 | -2.69 | 0.382 | 5.38 | 0.0789 | -- | 3.15 | 151,515.20 | -55.57 | -- | -63.59 | -- | -- | -- | -704.52 | -- | -- | -- | 0.00 | -- | -- | -- | -10.12 | -- | -- | -- |
| Scpharmaceuticals Inc | 0.00 | -29.43m | 84.36m | 21.00 | -- | 1.20 | -- | -- | -1.59 | -1.59 | 0.00 | 3.79 | 0.00 | -- | -- | 0.00 | -29.25 | -- | -31.76 | -- | -- | -- | -- | -- | -- | -- | 0.1209 | -- | -- | -- | -23.62 | -- | -- | -- |
| Anixa Biosciences Inc | 612.50k | -18.20m | 84.61m | 7.00 | -- | 12.87 | -- | 138.13 | -0.9642 | -0.9642 | 0.0323 | 0.3271 | 0.081 | -- | -- | -- | -244.96 | -90.92 | -293.85 | -107.15 | -- | -- | -3,024.76 | -239.87 | -- | -- | 0.00 | -- | 206.90 | 23.40 | -99.44 | -- | 124.06 | -- |
| Alpine Immune Sciences Inc | 390.00k | -43.56m | 84.68m | 48.00 | -- | 1.50 | -- | 217.14 | -2.95 | -2.95 | 0.0263 | 3.05 | 0.0053 | -- | -- | 8,125.00 | -58.95 | -20.72 | -64.05 | -22.34 | -- | -- | -11,169.74 | -1,033.15 | -- | -- | 0.062 | -- | -59.27 | -- | -357.06 | -- | 31.78 | -- |
| Fortress Biotech Inc | 27.46m | -52.68m | 84.80m | 88.00 | -- | 3.94 | -- | 3.09 | -1.21 | -1.42 | 0.5619 | 0.3298 | 0.1179 | 15.36 | 3.36 | 312,000.00 | -47.64 | -50.16 | -91.84 | -88.90 | 76.19 | -- | -403.97 | -608.22 | 2.78 | -12.03 | 0.6204 | -- | 55.88 | -- | -13.10 | -- | 190.55 | -- |
| Ovid Therapeutics Inc | 0.00 | -52.60m | 85.12m | 53.00 | -- | 1.49 | -- | -- | -2.03 | -2.03 | 0.00 | 1.48 | 0.00 | -- | -- | 0.00 | -72.39 | -- | -80.50 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 19.79 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -16.68m | 85.29m | 31.00 | -- | 259.07 | -- | -- | -0.812 | -0.812 | 0.00 | 0.0152 | 0.00 | -- | -- | 0.00 | -156.86 | -72.81 | -462.93 | -101.72 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -181.66 | -- | 27.86 | -- |
| Champions Oncology Inc | 24.27m | -252.00k | 86.88m | 92.00 | -- | 36.52 | 301.67 | 3.58 | -0.0323 | -0.0323 | 1.97 | 0.2048 | 2.70 | -- | 7.07 | 263,804.30 | -2.80 | -88.30 | -12.22 | -205.31 | 47.35 | 40.26 | -1.04 | -58.52 | -- | -- | 0.088 | -- | 31.34 | 19.45 | 78.56 | -- | 84.81 | -- |
| Genocea Biosciences Inc | 0.00 | -27.49m | 86.90m | 61.00 | -- | 8.99 | -- | -- | -2.33 | -2.33 | 0.00 | 0.4438 | 0.00 | -- | -- | 0.00 | -59.57 | -77.53 | -74.85 | -93.04 | -- | -- | -- | -17,466.86 | -- | -- | 0.6937 | -- | -- | -- | 50.96 | -- | -9.13 | -- |
Data as of Jul 22 2019. Currency figures normalised to Avadel Pharmaceuticals PLC's reporting currency: US Dollar USD
52.32%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Brandes Investment Partners LPas of 31 Mar 2019 | 7.05m | 18.88% |
| Broadfin Capital LLCas of 31 Mar 2019 | 3.10m | 8.31% |
| Deerfield Management Company LPas of 31 Mar 2019 | 2.72m | 7.29% |
| Brandes Investment Partners (Europe) Ltd.as of 31 Dec 2018 | 1.72m | 4.60% |
| Brown Capital Management LLCas of 31 Mar 2019 | 1.40m | 3.75% |
| Acadian Asset Management LLCas of 31 Mar 2019 | 843.98k | 2.26% |
| Tekla Capital Management LLCas of 31 Mar 2019 | 814.59k | 2.18% |
| Renaissance Technologies LLCas of 31 Mar 2019 | 658.34k | 1.76% |
| Morgan Stanley & Co. LLCas of 31 Mar 2019 | 642.37k | 1.72% |
| DWS Investment Management Americas, Inc.as of 31 Mar 2019 | 589.68k | 1.58% |
More ▼
Data from 31 Dec 2018 - 31 Mar 2019Source: FactSet Research Systems Inc.
